Stapelton, AE, Au-Yeung, M, Hooton, TM, Frederick, DN, Roberts, PL, Czaja, CA, Yarova-Yarovaya, Y, Fiedler, T, Cox, M and Stamm, WE. Clin Infect Dis. 2011 May;52(10):1212-7. doi: 10.1093/cid/cir183. Epub 2011 Apr 14.



Synopsis: LACTIN-V was tested in a randomized, blinded, placebo-controlled study of 100 women with a history of recurrent urinary tract infection (UTI). LACTIN-V following treatment for acute cystitis was associated with a reduction in recurrent UTI of ~50%. High-level vaginal colonization with L. crispatus (>106 16S rRNA gene copies per swab) throughout follow-up was associated with a significant reduction in recurrent UTI for women in the LACTIN-V group as compared to the placebo group (RR for LACTIN-V, .07; RR for placebo, 1.1; P < .01). This result suggested that treatment with the LACTIN-V L. crispatus strain conferred a significant advantage over repopulation of the vaginal microbiota with endogenous L. crispatus to prevent UTI recurrence.